Skip to main content
. 2022 Apr 29;12:7002. doi: 10.1038/s41598-022-10938-x

Figure 3.

Figure 3

Subgroup analysis: effects of different overlapping ratios in overall survival (OS) and time to next treatment (TTNT) between PPI and H2RA groups. (A) gefitinib cohort and (B) erlotinib cohort.